APO Research
Talk to an analyst

APO RESEARCH · REPORT

Phosphodiesterase (PDE) inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Phosphodiesterase (PDE) inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025182 pages

Choose your research edition.

Industry ResearchPhosphodiesterase (PDE) inhibitors Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Phosphodiesterase (PDE) inhibitors Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Phosphodiesterase (PDE) inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phosphodiesterase (PDE) inhibitors Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Phosphodiesterase (PDE) inhibitors Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Phosphodiesterase (PDE) inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Phosphodiesterase (PDE) inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Phosphodiesterase (PDE) inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Phosphodiesterase (PDE) inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Phosphodiesterase (PDE) inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Phosphodiesterase (PDE) inhibitors include Eli Lilly and Co., Pfizer Inc., GlaxoSmithKline Plc, Bayer AG and Vivus Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Phosphodiesterase (PDE) inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Phosphodiesterase (PDE) inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Phosphodiesterase (PDE) inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Phosphodiesterase (PDE) inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Phosphodiesterase (PDE) inhibitors Segment by Company

Eli Lilly and Co.

Pfizer Inc.

GlaxoSmithKline Plc

Bayer AG

Vivus Inc.

Phosphodiesterase (PDE) inhibitors Segment by Type

PDE10 selective inhibitors

PDE1 Selective Inhibitors

PDE2 Selective Inhibitors

PDE3 Selective Inhibitors

PDE4 selective inhibitors

PDE5 selective inhibitors

PDE7 selective inhibitors

Phosphodiesterase (PDE) inhibitors Segment by Application

Oral

Topical

Other

Phosphodiesterase (PDE) inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phosphodiesterase (PDE) inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phosphodiesterase (PDE) inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phosphodiesterase (PDE) inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Phosphodiesterase (PDE) inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Phosphodiesterase (PDE) inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Phosphodiesterase (PDE) inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Phosphodiesterase (PDE) inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Phosphodiesterase (PDE) inhibitors Industry Trends Table 2. Phosphodiesterase (PDE) inhibitors Industry Drivers Table 3. Phosphodiesterase (PDE) inhibitors Industry Opportunities and Challenges Table 4. Phosphodiesterase (PDE) inhibitors Industry Restraints Table 5. Global Phosphodiesterase (PDE) inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Phosphodiesterase (PDE) inhibitors Sales by Manufacturers (L) & (2021-2026) Table 8. Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Manufacturers Table 9. Global Phosphodiesterase (PDE) inhibitors Average Sales Price (US$/L) of Manufacturers (2021-2026) Table 10. Global Phosphodiesterase (PDE) inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Phosphodiesterase (PDE) inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Phosphodiesterase (PDE) inhibitors Manufacturers, Product Type & Application Table 13. Global Phosphodiesterase (PDE) inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Phosphodiesterase (PDE) inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of PDE10 selective inhibitors Table 17. Major Manufacturers of PDE1 Selective Inhibitors Table 18. Major Manufacturers of PDE2 Selective Inhibitors Table 19. Major Manufacturers of PDE3 Selective Inhibitors Table 20. Major Manufacturers of PDE4 selective inhibitors Table 21. Major Manufacturers of PDE5 selective inhibitors Table 22. Major Manufacturers of PDE7 selective inhibitors Table 23. Global Phosphodiesterase (PDE) inhibitors Sales by Type 2021 VS 2025 VS 2032 (L) Table 24. Global Phosphodiesterase (PDE) inhibitors Sales by Type (2021-2026) & (L) Table 25. Global Phosphodiesterase (PDE) inhibitors Sales by Type (2027-2032) & (L) Table 26. Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Type (2021-2026) Table 27. Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Type (2027-2032) Table 28. Global Phosphodiesterase (PDE) inhibitors Revenue by Type 2021 VS 2025 VS 2032 (L) Table 29. Global Phosphodiesterase (PDE) inhibitors Revenue by Type (2021-2026) & (L) Table 30. Global Phosphodiesterase (PDE) inhibitors Revenue by Type (2027-2032) & (L) Table 31. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Type (2021-2026) Table 32. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Oral Table 34. Major Manufacturers of Topical Table 35. Major Manufacturers of Other Table 36. Global Phosphodiesterase (PDE) inhibitors Sales by Application 2021 VS 2025 VS 2032 (L) Table 37. Global Phosphodiesterase (PDE) inhibitors Sales by Application (2021-2026) & (L) Table 38. Global Phosphodiesterase (PDE) inhibitors Sales by Application (2027-2032) & (L) Table 39. Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Application (2021-2026) Table 40. Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Application (2027-2032) Table 41. Global Phosphodiesterase (PDE) inhibitors Revenue by Application 2021 VS 2025 VS 2032 (L) Table 42. Global Phosphodiesterase (PDE) inhibitors Revenue by Application (2021-2026) & (L) Table 43. Global Phosphodiesterase (PDE) inhibitors Revenue by Application (2027-2032) & (L) Table 44. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Application (2021-2026) Table 45. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Application (2027-2032) Table 46. Global Phosphodiesterase (PDE) inhibitors Sales by Region: 2021 VS 2025 VS 2032 (L) Table 47. Global Phosphodiesterase (PDE) inhibitors Sales by Region (2021-2026) & (L) Table 48. Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Region (2021-2026) Table 49. Global Phosphodiesterase (PDE) inhibitors Sales Forecasted by Region (2027-2032) & (L) Table 50. Global Phosphodiesterase (PDE) inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Phosphodiesterase (PDE) inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (L) Table 52. North America Phosphodiesterase (PDE) inhibitors Sales by Country (2021-2026) & (L) Table 53. North America Phosphodiesterase (PDE) inhibitors Sales by Country (2027-2032) & (L) Table 54. Europe Phosphodiesterase (PDE) inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (L) Table 55. Europe Phosphodiesterase (PDE) inhibitors Sales by Country (2021-2026) & (L) Table 56. Europe Phosphodiesterase (PDE) inhibitors Sales by Country (2027-2032) & (L) Table 57. Asia Pacific Phosphodiesterase (PDE) inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (L) Table 58. Asia Pacific Phosphodiesterase (PDE) inhibitors Sales by Country (2021-2026) & (L) Table 59. Asia Pacific Phosphodiesterase (PDE) inhibitors Sales by Country (2027-2032) & (L) Table 60. South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (L) Table 61. South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Sales by Country (2021-2026) & (L) Table 62. South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Sales by Country (2027-2032) & (L) Table 63. Global Phosphodiesterase (PDE) inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Phosphodiesterase (PDE) inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Phosphodiesterase (PDE) inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Region (2021-2026) Table 67. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Region (2027-2032) Table 68. Eli Lilly and Co. Company Information Table 69. Eli Lilly and Co. Business Overview Table 70. Eli Lilly and Co. Phosphodiesterase (PDE) inhibitors Sales (L), Price (US$/L), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Eli Lilly and Co. Phosphodiesterase (PDE) inhibitors Product Portfolio Table 72. Eli Lilly and Co. Recent Development Table 73. Pfizer Inc. Company Information Table 74. Pfizer Inc. Business Overview Table 75. Pfizer Inc. Phosphodiesterase (PDE) inhibitors Sales (L), Price (US$/L), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Pfizer Inc. Phosphodiesterase (PDE) inhibitors Product Portfolio Table 77. Pfizer Inc. Recent Development Table 78. GlaxoSmithKline Plc Company Information Table 79. GlaxoSmithKline Plc Business Overview Table 80. GlaxoSmithKline Plc Phosphodiesterase (PDE) inhibitors Sales (L), Price (US$/L), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. GlaxoSmithKline Plc Phosphodiesterase (PDE) inhibitors Product Portfolio Table 82. GlaxoSmithKline Plc Recent Development Table 83. Bayer AG Company Information Table 84. Bayer AG Business Overview Table 85. Bayer AG Phosphodiesterase (PDE) inhibitors Sales (L), Price (US$/L), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Bayer AG Phosphodiesterase (PDE) inhibitors Product Portfolio Table 87. Bayer AG Recent Development Table 88. Vivus Inc. Company Information Table 89. Vivus Inc. Business Overview Table 90. Vivus Inc. Phosphodiesterase (PDE) inhibitors Sales (L), Price (US$/L), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Vivus Inc. Phosphodiesterase (PDE) inhibitors Product Portfolio Table 92. Vivus Inc. Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. Phosphodiesterase (PDE) inhibitors Distributors List Table 96. Phosphodiesterase (PDE) inhibitors Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Phosphodiesterase (PDE) inhibitors Product Image Figure 2. Global Phosphodiesterase (PDE) inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Phosphodiesterase (PDE) inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Phosphodiesterase (PDE) inhibitors Sales (2021-2032) & (L) Figure 5. Global Phosphodiesterase (PDE) inhibitors Average Price (US$/L) & (2021-2032) Figure 6. Global Top 5 and 10 Phosphodiesterase (PDE) inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. PDE10 selective inhibitors Image Figure 9. PDE1 Selective Inhibitors Image Figure 10. PDE2 Selective Inhibitors Image Figure 11. PDE3 Selective Inhibitors Image Figure 12. PDE4 selective inhibitors Image Figure 13. PDE5 selective inhibitors Image Figure 14. PDE7 selective inhibitors Image Figure 15. Global Phosphodiesterase (PDE) inhibitors Sales by Type (2021 VS 2025 VS 2032) & (L) Figure 16. Global Phosphodiesterase (PDE) inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Type (2021-2032) Figure 18. Global Phosphodiesterase (PDE) inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (L) Figure 19. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Type (2021-2032) Figure 21. Oral Image Figure 22. Topical Image Figure 23. Other Image Figure 24. Global Phosphodiesterase (PDE) inhibitors Sales by Application (2021 VS 2025 VS 2032) & (L) Figure 25. Global Phosphodiesterase (PDE) inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Application (2021-2032) Figure 27. Global Phosphodiesterase (PDE) inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (L) Figure 28. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Application (2021-2032) Figure 30. North America Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 31. North America Phosphodiesterase (PDE) inhibitors Sales Market Share by Country (2021-2032) Figure 32. U.S. Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 33. Canada Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 34. Mexico Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 35. Europe Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 36. Europe Phosphodiesterase (PDE) inhibitors Sales Market Share by Country (2021-2032) Figure 37. Germany Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 38. France Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 39. U.K. Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 40. Italy Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 41. Netherlands Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 42. Asia Pacific Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 43. Asia Pacific Phosphodiesterase (PDE) inhibitors Sales Market Share by Country (2021-2032) Figure 44. China Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 45. Japan Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 46. South Korea Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 47. Southeast Asia Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 48. India Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 49. Australia Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 50. South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 51. South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Sales Market Share by Country (2021-2032) Figure 52. Brazil Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 53. South Africa Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 54. Saudi Arabia Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 55. Turkey Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 56. Argentina Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 57. UAE Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 58. Egypt Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 59. Chile Phosphodiesterase (PDE) inhibitors Sales and Growth Rate (2021-2032) & (L) Figure 60. Global Phosphodiesterase (PDE) inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Phosphodiesterase (PDE) inhibitors Revenue (2021-2032) & (US$ Million) Figure 63. North America Phosphodiesterase (PDE) inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Phosphodiesterase (PDE) inhibitors Revenue (2021-2032) & (US$ Million) Figure 65. Europe Phosphodiesterase (PDE) inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Phosphodiesterase (PDE) inhibitors Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Phosphodiesterase (PDE) inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Phosphodiesterase (PDE) inhibitors Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Phosphodiesterase (PDE) inhibitors Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • PDE10 selective inhibitors
  • PDE1 Selective Inhibitors
  • PDE2 Selective Inhibitors
  • PDE3 Selective Inhibitors
  • PDE4 selective inhibitors
  • PDE5 selective inhibitors
  • PDE7 selective inhibitors
Applications
  • Oral
  • Topical
  • Other
Companies covered
  • Eli Lilly and Co.
  • Pfizer Inc.
  • GlaxoSmithKline Plc
  • Bayer AG
  • Vivus Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Phosphodiesterase (PDE) inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Phosphodiesterase (PDE) inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Phosphodiesterase (PDE) inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Phosphodiesterase (PDE) inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Phosphodiesterase (PDE) inhibitors Market Dynamics
  1. 2.1 Phosphodiesterase (PDE) inhibitors Industry Trends
  2. 2.2 Phosphodiesterase (PDE) inhibitors Industry Drivers
  3. 2.3 Phosphodiesterase (PDE) inhibitors Industry Opportunities and Challenges
  4. 2.4 Phosphodiesterase (PDE) inhibitors Industry Restraints
3 Phosphodiesterase (PDE) inhibitors Market by Manufacturers
  1. 3.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Phosphodiesterase (PDE) inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Phosphodiesterase (PDE) inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Phosphodiesterase (PDE) inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Phosphodiesterase (PDE) inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Phosphodiesterase (PDE) inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Phosphodiesterase (PDE) inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Phosphodiesterase (PDE) inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Phosphodiesterase (PDE) inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Phosphodiesterase (PDE) inhibitors Tier 1, Tier 2, and Tier 3
4 Phosphodiesterase (PDE) inhibitors Market by Type
  1. 4.1 Phosphodiesterase (PDE) inhibitors Type Introduction
  2. 4.1.1 PDE10 selective inhibitors
  3. 4.1.2 PDE1 Selective Inhibitors
  4. 4.1.3 PDE2 Selective Inhibitors
  5. 4.1.4 PDE3 Selective Inhibitors
  6. 4.1.5 PDE4 selective inhibitors
  7. 4.1.6 PDE5 selective inhibitors
  8. 4.1.7 PDE7 selective inhibitors
  9. 4.2 Global Phosphodiesterase (PDE) inhibitors Sales by Type
  10. 4.2.1 Global Phosphodiesterase (PDE) inhibitors Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Phosphodiesterase (PDE) inhibitors Sales by Type (2021-2032)
  12. 4.2.3 Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Type (2021-2032)
  13. 4.3 Global Phosphodiesterase (PDE) inhibitors Revenue by Type
  14. 4.3.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Type (2021-2032)
  16. 4.3.3 Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Type (2021-2032)
5 Phosphodiesterase (PDE) inhibitors Market by Application
  1. 5.1 Phosphodiesterase (PDE) inhibitors Application Introduction
  2. 5.1.1 Oral
  3. 5.1.2 Topical
  4. 5.1.3 Other
  5. 5.2 Global Phosphodiesterase (PDE) inhibitors Sales by Application
  6. 5.2.1 Global Phosphodiesterase (PDE) inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Phosphodiesterase (PDE) inhibitors Sales by Application (2021-2032)
  8. 5.2.3 Global Phosphodiesterase (PDE) inhibitors Sales Market Share by Application (2021-2032)
  9. 5.3 Global Phosphodiesterase (PDE) inhibitors Revenue by Application
  10. 5.3.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Application (2021-2032)
  12. 5.3.3 Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Application (2021-2032)
6 Global Phosphodiesterase (PDE) inhibitors Sales by Region
  1. 6.1 Global Phosphodiesterase (PDE) inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Phosphodiesterase (PDE) inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Phosphodiesterase (PDE) inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Phosphodiesterase (PDE) inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Phosphodiesterase (PDE) inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Phosphodiesterase (PDE) inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Phosphodiesterase (PDE) inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Phosphodiesterase (PDE) inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Phosphodiesterase (PDE) inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Phosphodiesterase (PDE) inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Phosphodiesterase (PDE) inhibitors Revenue by Region
  1. 7.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Region
  2. 7.1.1 Global Phosphodiesterase (PDE) inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Phosphodiesterase (PDE) inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Phosphodiesterase (PDE) inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Phosphodiesterase (PDE) inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Phosphodiesterase (PDE) inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Phosphodiesterase (PDE) inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Phosphodiesterase (PDE) inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Phosphodiesterase (PDE) inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Phosphodiesterase (PDE) inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Phosphodiesterase (PDE) inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Phosphodiesterase (PDE) inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly and Co.
  2. 8.1.1 Eli Lilly and Co. Company Information
  3. 8.1.2 Eli Lilly and Co. Business Overview
  4. 8.1.3 Eli Lilly and Co. Phosphodiesterase (PDE) inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly and Co. Phosphodiesterase (PDE) inhibitors Product Portfolio
  6. 8.1.5 Eli Lilly and Co. Recent Developments
  7. 8.2 Pfizer Inc.
  8. 8.2.1 Pfizer Inc. Company Information
  9. 8.2.2 Pfizer Inc. Business Overview
  10. 8.2.3 Pfizer Inc. Phosphodiesterase (PDE) inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc. Phosphodiesterase (PDE) inhibitors Product Portfolio
  12. 8.2.5 Pfizer Inc. Recent Developments
  13. 8.3 GlaxoSmithKline Plc
  14. 8.3.1 GlaxoSmithKline Plc Company Information
  15. 8.3.2 GlaxoSmithKline Plc Business Overview
  16. 8.3.3 GlaxoSmithKline Plc Phosphodiesterase (PDE) inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GlaxoSmithKline Plc Phosphodiesterase (PDE) inhibitors Product Portfolio
  18. 8.3.5 GlaxoSmithKline Plc Recent Developments
  19. 8.4 Bayer AG
  20. 8.4.1 Bayer AG Company Information
  21. 8.4.2 Bayer AG Business Overview
  22. 8.4.3 Bayer AG Phosphodiesterase (PDE) inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer AG Phosphodiesterase (PDE) inhibitors Product Portfolio
  24. 8.4.5 Bayer AG Recent Developments
  25. 8.5 Vivus Inc.
  26. 8.5.1 Vivus Inc. Company Information
  27. 8.5.2 Vivus Inc. Business Overview
  28. 8.5.3 Vivus Inc. Phosphodiesterase (PDE) inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Vivus Inc. Phosphodiesterase (PDE) inhibitors Product Portfolio
  30. 8.5.5 Vivus Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Phosphodiesterase (PDE) inhibitors Value Chain Analysis
  2. 9.1.1 Phosphodiesterase (PDE) inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Phosphodiesterase (PDE) inhibitors Production Mode & Process
  6. 9.2 Phosphodiesterase (PDE) inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Phosphodiesterase (PDE) inhibitors Distributors
  9. 9.2.3 Phosphodiesterase (PDE) inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst